Experimental COVID-19 vaccine trial begins

Seattle: U.S researchers have administered first experimental COVID-19 vaccine as the world.

The vaccine, code-named mRNA-1273, has been developed by the NIH and Massachusetts-based biotechnology company Moderna Inc. The phase 1 study aims to test three different doses of the mRNA-1273 vaccine ad hopes to recruit 45 healthy adults for the initial trial. Participants will receive two shots of the vaccine, 28 days apart and will be monitored to evaluate both the safety and immunogenicity of the vaccine.

Jennifer Haller – 43, the first person to be injected by the experimental vaccine, hoped for the success of this trial. In an interview with TIME magazine she stated, “I hope that we get to a working vaccine quickly and that we can save lives and people can go back to life as soon as possible.”

Dr. Tal Zaks, Chief Medical Officer at Moderna said, “Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority.”

“This Phase 1 study, launched in record speed, is an important first step toward achieving that goal,” he added.

The vaccine cannot cause COVID-19, as it does not contain the virus itself as compared to various other vaccines.

The Seattle research institute is part of a government network of centers that test all kinds of vaccines, and was chosen for the coronavirus vaccine study before COVID-19 began spreading widely in Washington state.

The study aims to enroll healthy people aged 18-55 from Seattle to conduct further tests and analyze the results of the experimental drug.

Various research groups have been striving to develop a vaccine for COVID-19 coronavirus to curb its spread which has affected more than 170,400 people spanning across 140 countries.